EMD Serono’s Mavenclad Edges Past Novartis’ Gilenya in the Recent Switch Segment of Canada’s Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier
Even with the recent favorable conclusion to pan-Canadian Pharmaceutical Alliance negotiations, the prescriber base for Roche’s Ocrevus may be nearing a plateau requiring existing prescribers to fuel the majority of anticipated brand growth, according to the inaugural Canada report from Spherix Global Insights Download Report Overview EXTON, Pa., May 28, 2019 ― Therapeutic choice for […]
Influence of Gender and Age in Use of Ocrelizumab for PPMS Patients Among US Neurologists
Authors: Robert T. Naismith; Patricia K. Coyle; Shiv Saidha; Jennifer Robinson; Virginia R. Schobel OBJECTIVE: To evaluate current use of ocrelizumab in primary progressive multiple sclerosis (PPMS) patients. We hypothesized that ocrelizumab would be predominantly used in younger, male patients. BACKGROUND: In the phase 3 ORATORIO PPMS trial of ocrelizumab versus placebo, there was no […]
Identifying SPMS: Are U.S. Neurologists Aligned on the Most Influential Disease and Patient Metrics?
Authors: Robert T. Naismith; Patricia K. Coyle; Shiv Saidha; Jennifer Robinson; Virginia R. Schobel OBJECTIVE: To identify disease and patient characteristics used to diagnose secondary progressive (SPMS). We hypothesized that evidence of progression independent of relapse activity (PIRA) would be the most relied upon factor, along with other markers of neurodegeneration/progression. BACKGROUND: SPMS is a […]
Biogen’s Tecfidera Share of the Multiple Sclerosis Switch Segment Continues a Three-Year Downward Trend to the Benefit of Novartis’ Gilenya and Genentech’s Ocrevus
EMD Serono and Novartis will have the greatest opportunity to drive patient switches to Mavenclad and Mayzent, respectively, within the first six months following transition to secondary progressive multiple sclerosis, according to a new audit by Spherix Global Insights Download Report Overview EXTON, Pa., April 29, 2019 ― According to Spherix’s new RealWorld Dynamix™: DMT […]
Preferential First-Line Use of Biogen’s Tecfidera and Continued Uptake of Merck KGaA’s Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year
Assuming approval and dependent upon the label in Europe, Novartis’ Mayzent should be well positioned for strong adoption in active secondary progressive multiple sclerosis and transitioning relapsing-remitting multiple sclerosis, although low unaided awareness of the latter patient type may hamper uptake without a focused educational strategy, according to the prelaunch assessment in a new report […]
Spherix Global Insights’ Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva’s Ajovy Early Launch Success
Ajovy’s lack of an autoinjector may not be an obstacle for the brand as neurologists and migraine specialists report a sizeable percentage of patients treated with Amgen/Novartis’ Aimovig and Eli Lilly’s Emgality choosing to use the prefilled syringe option over the heavily promoted Aimovig SureClick and Emgality Pen devices. Download Report Overview EXTON, Pa., March 25, […]
DMT Choice for Your MS Is Your Decision
From: Multiple Sclerosis News Today By: Ed Tobias
Two Years After Launch of Genentech’s Ocrevus, US Neurologists Report a Significant and Persistent Increase in the Treatment of Patients with Primary Progressive Multiple Sclerosis
According to a new report from Spherix Global Insights, Novartis’ Mayzent is anticipated to grow the size of the secondary progressive multiple sclerosis segment in the United States, decreasing the influence of the relapsing remitting multiple sclerosis segment on market dynamics Download Report Overview EXTON, Pa., March 12, 2019 ―Expanding adoption of Genentech’s Ocrevus among […]
Spherix Global Insights’ Recent Multiple Sclerosis Chart Audit Shows That the Current First-Line Opportunity for High-Efficacy Disease-Modifying Therapies, Including Genentech’s Ocrevus and Biogen’s Tysabri, May Be Limited By A Small Unfavorable Prognosis Segment Size
Conversely, new start shares for Teva’s Copaxone, Biogen’s Tecfidera, Genzyme’s Aubagio, and EMD Serono’s Rebif are buoyed by preferential prescribing among the high volume of patients presenting with a favorable long-term prognosis at the time of therapy initiation Download Report Overview EXTON, Pa., February 12, 2019 ―With increasing focus on the early implementation of high-efficacy […]
Spherix Global Insights’ Quarterly Update on the US Migraine Prevention Market Confirms the Value of First-to-Market Status for Amgen and Novartis’ Aimovig as Teva’s Ajovy and Eli Lilly’s Emgality Strive to Differentiate From the Class Leader and Each Other
With insurance coverage and patient cost frequent barriers to greater anti-CGRP brand uptake irrespective of the availability of free drug voucher programs, topiramate and Allergan’s Botox continue to be US neurologists and migraine/headache specialists’ most preferred and most prescribed migraine preventive therapies, according to a new report from Spherix Global Insights Download Report Overview EXTON, […]
